GlassScriptPhysician profile
Orell R Williams
NPI 1972559755
$6,051.09
in general payments reported to CMS, 2019-2025
34 companies · $1,717 in 2025
The $1,717 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2021: $148 · 2022: $1,177 · 2023: $1,213 · 2024: $1,330 · 2025: $1,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,259.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,046.33 | 2022-2025 | Vraylar, Creon, Linzess |
| Novo Nordisk INC | $862.49 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $741.60 | 2019-2025 | Airsupra, Farxiga, Breztri |
| E.R. Squibb & Sons, L.L.C. | $649.39 | 2019-2025 | Eliquis, Camzyos |
| Galderma Laboratories, L.P. | $396.10 | 2021-2025 | |
| Lilly USA, LLC | $354.83 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $249.74 | 2019 | |
| Pfizer INC. | $238.22 | 2019-2025 | |
| Kestra Medical Technology Services, INC. | $170.93 | 2025 | Assure Wcd |
| Boston Scientific Corporation | $145.35 | 2024-2025 | Watchman Access System |
| Aimmune Therapeutics, INC. | $104.52 | 2024-2025 | Zenpep |
| Amgen INC. | $104.47 | 2024 | Repatha, Otezla, Tezspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.55 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $83.51 | 2024-2025 | Rexulti |
| Nestle Healthcare Nutrition INC. | $83.10 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $80.71 | 2024-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $71.40 | 2025 | Rexulti |
| Astellas Pharma US INC | $70.84 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $61.37 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Ibsa Pharma INC. | $59.96 | 2022-2023 | Tirosint, Licart |
| Alnylam Pharmaceuticals INC. | $52.55 | 2024-2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $52.21 | 2024 | Xarelto |
| Sumitomo Pharma America, INC. | $51.42 | 2025 | Gemtesa |
| Mylan Specialty L.P. | $39.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.78 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.34 | 2022 | |
| Next Science LLC | $20.18 | 2023 | Xperience, Blastx, Surgx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.00 | 2019 | |
| Glaxosmithkline, LLC. | $19.76 | 2025 | Penmenvy |
| Smith+Nephew, INC. | $17.50 | 2023 | Oasis, Grafix Pl |
| Idorsia Pharmaceuticals US INC | $17.19 | 2022 | |
| Medtronic Vascular, INC. | $17.14 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $16.99 | 2024 | Baqsimi |
| Merck Sharp & Dohme LLC | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orell Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.